Coactivator P300 promotes hepatic steatosis in obesity

共激活剂 P300 促进肥胖患者的肝脂肪变性

基本信息

  • 批准号:
    9902424
  • 负责人:
  • 金额:
    $ 54.79万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2019
  • 资助国家:
    美国
  • 起止时间:
    2019-04-01 至 2024-03-31
  • 项目状态:
    已结题

项目摘要

Obesity, which has reached epidemic proportions worldwide, is associated with an increased risk of numerous metabolic abnormalities including nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes (T2D). NAFLD is increasingly common, and now affects over 30% of the population in the USA. Insulin resistance is a hallmark of type 2 diabetes and obesity, and excessive accumulation of triglycerides is a hallmark of NAFLD. Because intact insulin signaling is required for lipogenesis, the defect in insulin signaling should reduce hepatic triglyceride content; however, patients with obesity and type 2 diabetes commonly have nonalcoholic fatty liver disease (NAFLD), and the majority of patients with NAFLD are also obese and/or have T2D. The underlying mechanisms leading to the paradoxical co-occurrence of hepatic steatosis and insulin resistance are not well understood. Previous studies have shown that overexpression of the deacetylase Sirtuin 1 or treatment with resveratrol, a Sirtuin 1 activator, not only improved hepatic steatosis, but also restored insulin sensitivity in tissues with insulin resistance. These results suggest that an acetyltransferase can antagonize Sirtuin 1’s activity, causing hepatic steatosis and insulin resistance. We observed a significant increase in hepatic acetyltransferase P300’s protein levels in high-fat diet (HFD) fed mice and ob/ob mice through the IRE1-XBP1s pathway in the endoplasmic reticulum stress response. Depletion of P300 or inhibition of P300 acetyltransferase activity decreased lipogenic gene expression and increased insulin sensitivity. Therefore, P300 uniquely increases lipogenesis and disrupts insulin signaling in the liver of obesity. We will assess the role of elevated P300 in promoting hepatic lipogenesis in Aim 1. We will define the molecular mechanisms of P300’s promotion of hepatic steatosis in Aim 2. We propose to determine whether P300 acetyltransferase activity is a therapeutic target for obesity/T2D in Aim 3. We believe that P300 plays an important role in the development of NAFLD and insulin resistance, linking inflammatory and metabolic diseases.
肥胖在世界范围内已达到流行病的程度,与许多疾病的风险增加有关

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Ling He其他文献

Ling He的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Ling He', 18)}}的其他基金

Coactivator P300 promotes hepatic steatosis in obesity
共激活剂 P300 促进肥胖患者的肝脂肪变性
  • 批准号:
    10597095
  • 财政年份:
    2019
  • 资助金额:
    $ 54.79万
  • 项目类别:
Coactivator P300 promotes hepatic steatosis in obesity
共激活剂 P300 促进肥胖患者的肝脂肪变性
  • 批准号:
    9755549
  • 财政年份:
    2019
  • 资助金额:
    $ 54.79万
  • 项目类别:
Coactivator P300 promotes hepatic steatosis in obesity
共激活剂 P300 促进肥胖患者的肝脂肪变性
  • 批准号:
    10365981
  • 财政年份:
    2019
  • 资助金额:
    $ 54.79万
  • 项目类别:
Activation of the cAMP-PKA pathway antagonizes metformin action
cAMP-PKA 通路的激活会拮抗二甲双胍的作用
  • 批准号:
    9186543
  • 财政年份:
    2015
  • 资助金额:
    $ 54.79万
  • 项目类别:
Activation of the cAMP-PKA pathway antagonizes metformin action
cAMP-PKA 通路的激活会拮抗二甲双胍的作用
  • 批准号:
    9008164
  • 财政年份:
    2015
  • 资助金额:
    $ 54.79万
  • 项目类别:
The Distinct Role of CBP and p300 in Regulating Hepatic Glucose Production
CBP 和 p300 在调节肝葡萄糖生成中的独特作用
  • 批准号:
    8310339
  • 财政年份:
    2011
  • 资助金额:
    $ 54.79万
  • 项目类别:
The Distinct Role of CBP and p300 in Regulating Hepatic Glucose Production
CBP 和 p300 在调节肝葡萄糖生成中的独特作用
  • 批准号:
    8328726
  • 财政年份:
    2011
  • 资助金额:
    $ 54.79万
  • 项目类别:
The Distinct Role of CBP and p300 in Regulating Hepatic Glucose Production
CBP 和 p300 在调节肝葡萄糖生成中的独特作用
  • 批准号:
    8515392
  • 财政年份:
    2011
  • 资助金额:
    $ 54.79万
  • 项目类别:
The Distinct Role of CBP and p300 in Regulating Hepatic Glucose Production
CBP 和 p300 在调节肝葡萄糖生成中的独特作用
  • 批准号:
    7989326
  • 财政年份:
    2010
  • 资助金额:
    $ 54.79万
  • 项目类别:
The Distinct Role of CBP and p300 in Regulating Hepatic Glucose Production
CBP 和 p300 在调节肝葡萄糖生成中的独特作用
  • 批准号:
    8115793
  • 财政年份:
    2010
  • 资助金额:
    $ 54.79万
  • 项目类别:

相似海外基金

Dissecting out differential molecular phenotypes across Lysine(K) AcetylTransferase mutations in mouse development
剖析小鼠发育过程中赖氨酸(K)乙酰转移酶突变的差异分子表型
  • 批准号:
    10727966
  • 财政年份:
    2023
  • 资助金额:
    $ 54.79万
  • 项目类别:
Targeting lysine acetyltransferase MOF/KAT8 in lung cancer
靶向赖氨酸乙酰转移酶 MOF/KAT8 在肺癌中的作用
  • 批准号:
    10601761
  • 财政年份:
    2023
  • 资助金额:
    $ 54.79万
  • 项目类别:
Defining the cell-type specific role of histone acetyltransferase KAT2a in nucleus accumbens D1 medium spiny neurons as a driver of cocaine use disorder
定义组蛋白乙酰转移酶 KAT2a 在伏隔核 D1 中型多棘神经元中作为可卡因使用障碍驱动因素的细胞类型特异性作用
  • 批准号:
    10679238
  • 财政年份:
    2023
  • 资助金额:
    $ 54.79万
  • 项目类别:
Roles of lysine acetyltransferase 6 complexes in cerebral development and neurodevelopmental disorders
赖氨酸乙酰转移酶 6 复合物在大脑发育和神经发育障碍中的作用
  • 批准号:
    479754
  • 财政年份:
    2023
  • 资助金额:
    $ 54.79万
  • 项目类别:
    Operating Grants
Examination of the Histone Acetyltransferase CBP in the Remodelling of Thermogenic Adipose Tissues
组蛋白乙酰转移酶 CBP 在生热脂肪组织重塑中的检测
  • 批准号:
    486467
  • 财政年份:
    2022
  • 资助金额:
    $ 54.79万
  • 项目类别:
    Studentship Programs
Development of p300/CBP histone acetyltransferase inhibitors for oncogene-driven cancers
开发用于癌基因驱动癌症的 p300/CBP 组蛋白乙酰转移酶抑制剂
  • 批准号:
    10344246
  • 财政年份:
    2022
  • 资助金额:
    $ 54.79万
  • 项目类别:
Nuclear activity of carnitine acetyltransferase
肉毒碱乙酰转移酶的核活性
  • 批准号:
    RGPIN-2018-06089
  • 财政年份:
    2022
  • 资助金额:
    $ 54.79万
  • 项目类别:
    Discovery Grants Program - Individual
Development of p300/CBP histone acetyltransferase inhibitors for oncogene-driven cancers
开发用于癌基因驱动癌症的 p300/CBP 组蛋白乙酰转移酶抑制剂
  • 批准号:
    10627744
  • 财政年份:
    2022
  • 资助金额:
    $ 54.79万
  • 项目类别:
Structural and functional studies of histone acetyltransferase complexes
组蛋白乙酰转移酶复合物的结构和功能研究
  • 批准号:
    RGPIN-2018-03951
  • 财政年份:
    2022
  • 资助金额:
    $ 54.79万
  • 项目类别:
    Discovery Grants Program - Individual
Characterizing the role of the NuA3 histone acetyltransferase complex during transcription
表征 NuA3 组蛋白乙酰转移酶复合物在转录过程中的作用
  • 批准号:
    557615-2021
  • 财政年份:
    2022
  • 资助金额:
    $ 54.79万
  • 项目类别:
    Postdoctoral Fellowships
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了